Research Reference
Glutathione 600mg
Endogenous master antioxidant tripeptide — 600mg strength reference
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Glutathione (GSH) is a small endogenous tripeptide composed of glutamate, cysteine, and glycine. It is one of the most abundant intracellular antioxidants in the human body and plays a central role in redox homeostasis, detoxification, and immune function. The 600mg strength refers to a common compounded preparation concentration referenced in clinical and aesthetic wellness literature.
Endogenous glutathione is synthesized primarily in the liver and exists in reduced (GSH) and oxidized (GSSG) forms. The ratio between the two is used as a marker of cellular oxidative stress. Levels decline with age, stress, poor nutrition, and certain disease states, which has driven research interest in exogenous glutathione supplementation.
The 600mg preparation is frequently referenced in aesthetic and integrative medicine contexts, particularly in skin-brightening and antioxidant protocols. Research on its bioavailability and clinical effect remains limited and mixed.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 600 mg vial. Resulting concentration: 300 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 100 mg | 33.33 units | 0.33 mL | SubQ, dailyWeeks 1–2 — 33 units (0.33 mL) |
| 150 mg | 50 units | 0.5 mL | SubQ, dailyWeeks 3–4 — 50 units (0.50 mL) |
| 200 mg | 66.67 units | 0.67 mL | SubQ, dailyWeeks 5–8 — 67 units (0.67 mL) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Glutathione is supplied as a compounded lyophilized vial for subcutaneous use. Compounded research-peptide forms are not FDA-approved.
For a 600 mg vial reconstituted with 2 mL bacteriostatic water, the concentration is 300 mg/mL. Gently swirl — do not shake — and store refrigerated. Compounded forms are not FDA-approved.
U-100 syringe draws (at 300 mg/mL):
| Dose | Volume | Units on U-100 | | --- | --- | --- | | 100 mg | 0.33 mL | 33 units | | 150 mg | 0.50 mL | 50 units | | 200 mg | 0.67 mL | 67 units |
Cycling Protocol
Community protocols describe a gradual SubQ titration: 100 mg daily for Weeks 1–2, 150 mg daily for Weeks 3–4, and 200 mg daily for Weeks 5–8, sometimes continued as ongoing antioxidant support. No standardized cycle is established; compounded glutathione is not FDA-approved.
Routes of Administration
Subcutaneous injection: Administered daily into the abdomen or thigh. Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Antioxidant + Vitamin C | Glutathione 600mg SubQ + Vitamin C (oral) | Combined antioxidant support common in integrative protocols | | Skin-Brightening Protocol | Glutathione 600mg SubQ + NAC (oral) | NAC supports endogenous glutathione synthesis | | Liver Support | Glutathione 600mg SubQ + Milk Thistle / NAC (oral) | Detoxification and hepatoprotection regimens |
Community integrative protocols describe spacing glutathione injections from other compounds and introducing one variable at a time to assess individual response.
Side Effects & Safety
Reported effects in the research literature include:
- Gastrointestinal discomfort when taken orally, including bloating and cramping.
- Allergic or hypersensitivity reactions in rare cases, particularly with intravenous administration.
- Skin lightening or brightening effects reported in some aesthetic protocols, the mechanism and safety of which remain debated.
- Potential interference with certain chemotherapy agents, as antioxidants may reduce oxidative cytotoxicity used in some cancer treatments.
- Bronchospasm risk has been reported in rare cases of inhaled or nebulized glutathione in asthmatic patients.
Oral glutathione is poorly bioavailable because it is degraded by digestive enzymes; this has driven interest in intravenous, sublingual, and liposomal delivery routes, each with its own safety considerations.
Research Basis
The evidence base for exogenous glutathione is mixed and route-dependent:
- Oral supplementation studies have produced inconsistent results on whether circulating glutathione levels meaningfully rise, owing to degradation in the gastrointestinal tract.
- Intravenous administration reliably raises blood levels, but clinical outcome studies remain limited in size and duration.
- Skin-brightening claims are supported by small studies and extensive anecdotal use, particularly in Southeast Asian aesthetic medicine, but large randomized controlled trials are lacking.
- Antioxidant and detoxification roles are well-established biochemically, but translating this into measurable clinical benefit for specific conditions remains an active research area.
Glutathione is not FDA-approved for the treatment of any disease in the United States. Its use in aesthetic and wellness settings is off-label and largely unregulated. BioMaxFit does not sell, promote, or recommend glutathione or any preparation of it.